JP2001503429A - （４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用 - Google Patents

（４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用

Info

Publication number: JP2001503429A
Authority: JP; Japan
Prior art keywords: compound; hiv; formula; pharmaceutically acceptable; reverse transcriptase
Prior art date: 1996-11-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP52168298A

Other languages

English (en)

Japanese (ja)

Inventor

ロジャース，ジェイムズ，デイヴィッド．

ラム，パトリック，ユク―スン．

Original Assignee

デュポンファーマシューティカルズカンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-08

Filing date

1997-11-04

Publication date

2001-03-13

1997-11-04 Application filed by デュポンファーマシューティカルズカンパニー filed Critical デュポンファーマシューティカルズカンパニー

2001-03-13 Publication of JP2001503429A publication Critical patent/JP2001503429A/ja

Status Pending legal-status Critical Current

Links

239000004030 hiv protease inhibitor Substances 0.000 title claims description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title description 6
YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title description 3
HHVIPGYWIHLNFW-UHFFFAOYSA-N 4-benzyl-1,3-diazepin-2-one Chemical class O=C1N=CC=CC(CC=2C=CC=CC=2)=N1 HHVIPGYWIHLNFW-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 138
238000000034 method Methods 0.000 claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 37
239000000651 prodrug Substances 0.000 claims abstract description 22
229940002612 prodrug Drugs 0.000 claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
208000031886 HIV Infections Diseases 0.000 claims description 22
208000037357 HIV infectious disease Diseases 0.000 claims description 21
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 21
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 21
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 19
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 12
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 12
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 11
229960001936 indinavir Drugs 0.000 claims description 11
229960000311 ritonavir Drugs 0.000 claims description 9
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 9
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 8
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 8
229960001852 saquinavir Drugs 0.000 claims description 8
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 7
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 6
229940122440 HIV protease inhibitor Drugs 0.000 claims description 6
NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 claims description 6
108010075606 kynostatin 272 Proteins 0.000 claims description 6
229960000884 nelfinavir Drugs 0.000 claims description 6
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 4
BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 claims description 2
238000003556 assay Methods 0.000 abstract description 16
239000003112 inhibitor Substances 0.000 abstract description 11
108010010369 HIV Protease Proteins 0.000 abstract description 10
239000003153 chemical reaction reagent Substances 0.000 abstract description 5
230000009385 viral infection Effects 0.000 abstract description 3
238000009007 Diagnostic Kit Methods 0.000 abstract description 2
208000036142 Viral infection Diseases 0.000 abstract description 2
241000725303 Human immunodeficiency virus Species 0.000 description 33
239000004480 active ingredient Substances 0.000 description 24
210000004027 cell Anatomy 0.000 description 24
239000000523 sample Substances 0.000 description 24
108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
241000700605 Viruses Species 0.000 description 18
239000003814 drug Substances 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 16
108091005804 Peptidases Proteins 0.000 description 13
239000004365 Protease Substances 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 12
239000003826 tablet Substances 0.000 description 12
239000002552 dosage form Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 11
210000002845 virion Anatomy 0.000 description 11
239000002775 capsule Substances 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
102100034343 Integrase Human genes 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
239000002253 acid Substances 0.000 description 9
230000000840 anti-viral effect Effects 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 8
239000002609 medium Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
210000001124 body fluid Anatomy 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
208000030507 AIDS Diseases 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108010090804 Streptavidin Proteins 0.000 description 6
108020000999 Viral RNA Proteins 0.000 description 6
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
235000013877 carbamide Nutrition 0.000 description 6
125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
239000002243 precursor Substances 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
-1 Cyclic ureas Chemical class 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
239000010839 body fluid Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
239000002777 nucleoside Substances 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
150000002118 epoxides Chemical class 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
VCYQENLVFRTJIC-UHFFFAOYSA-N 4-cyano-n-[3-[cyclopropyl-(4-hydroxy-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyran-3-yl)methyl]phenyl]benzenesulfonamide Chemical compound OC=1C=2CCCCCCC=2OC(=O)C=1C(C=1C=C(NS(=O)(=O)C=2C=CC(=CC=2)C#N)C=CC=1)C1CC1 VCYQENLVFRTJIC-UHFFFAOYSA-N 0.000 description 3
ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 3
229940126062 Compound A Drugs 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
101100366282 Mus musculus Spats1 gene Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003443 antiviral agent Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013066 combination product Substances 0.000 description 3
229940127555 combination product Drugs 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
229940093915 gynecological organic acid Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000008297 liquid dosage form Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
125000003835 nucleoside group Chemical group 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930194542 Keto Natural products 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010076039 Polyproteins Proteins 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108700022715 Viral Proteases Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000003513 alkali Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
229940121357 antivirals Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
238000011461 current therapy Methods 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000000468 ketone group Chemical group 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
150000003672 ureas Chemical class 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ANUSGJXVCFPWMQ-UHFFFAOYSA-N 1-(2-phenylethyl)-3-(1,3-thiazol-2-yl)thiourea Chemical compound N=1C=CSC=1NC(=S)NCCC1=CC=CC=C1 ANUSGJXVCFPWMQ-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
WHFRDXVXYMGAJD-UHFFFAOYSA-N 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1h-pyridin-2-one Chemical compound O=C1NC(C)=C(CC)C=C1NCC1=NC2=C(Cl)C=CC(Cl)=C2O1 WHFRDXVXYMGAJD-UHFFFAOYSA-N 0.000 description 1
IZOOGWHCNUKRTO-UHFFFAOYSA-N 4,5-dibenzyl-1,3-diazepin-2-one Chemical compound C=1C=CC=CC=1CC1=NC(=O)N=CC=C1CC1=CC=CC=C1 IZOOGWHCNUKRTO-UHFFFAOYSA-N 0.000 description 1
GUUKPGIJZYZERR-UHFFFAOYSA-N 5-(bromomethyl)-2-fluorobenzonitrile Chemical compound FC1=CC=C(CBr)C=C1C#N GUUKPGIJZYZERR-UHFFFAOYSA-N 0.000 description 1
LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000029483 Acquired immunodeficiency Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108091005502 Aspartic proteases Proteins 0.000 description 1
102000035101 Aspartic proteases Human genes 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
229940086609 Lipase inhibitor Drugs 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000208474 Protea Species 0.000 description 1
102000028391 RNA cap binding Human genes 0.000 description 1
108091000106 RNA cap binding Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
101150057615 Syn gene Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108091034135 Vault RNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
WEUCTTBUEWINIJ-UHFFFAOYSA-N acetic acid;zinc;dihydrate Chemical compound O.O.[Zn].CC(O)=O WEUCTTBUEWINIJ-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000013096 assay test Methods 0.000 description 1
DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
150000003842 bromide salts Chemical class 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
CNWSQCLBDWYLAN-UHFFFAOYSA-N butylurea Chemical compound CCCCNC(N)=O CNWSQCLBDWYLAN-UHFFFAOYSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229940045996 isethionic acid Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
239000004137 magnesium phosphate Substances 0.000 description 1
229960002261 magnesium phosphate Drugs 0.000 description 1
229910000157 magnesium phosphate Inorganic materials 0.000 description 1
235000010994 magnesium phosphates Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical class C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229950000244 sulfanilic acid Drugs 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
239000005723 virus inoculator Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP52168298A 1996-11-08 1997-11-04 （４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用 Pending JP2001503429A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US74710396A	1996-11-08	1996-11-08
US2974696P	1996-11-08	1996-11-08
US08/747,103		1996-11-08
US60/029,746		1996-11-08
PCT/US1997/020036 WO1998020009A1 (en)	1996-11-08	1997-11-04	(4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor

Publications (1)

Publication Number	Publication Date
JP2001503429A true JP2001503429A (ja)	2001-03-13

Family

ID=26705295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP52168298A Pending JP2001503429A (ja)	1996-11-08	1997-11-04	（４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用

Country Status (19)

Country	Link
EP (1)	EP0937066A1 (cs)
JP (1)	JP2001503429A (cs)
KR (1)	KR20000053123A (cs)
CN (1)	CN1235601A (cs)
AU (1)	AU722489B2 (cs)
BR (1)	BR9712755A (cs)
CA (1)	CA2270963A1 (cs)
CZ (1)	CZ157499A3 (cs)
EA (1)	EA001154B1 (cs)
EE (1)	EE9900187A (cs)
HU (1)	HUP9904143A3 (cs)
IL (1)	IL129726A0 (cs)
LV (1)	LV12374B (cs)
NO (1)	NO992229L (cs)
NZ (1)	NZ335919A (cs)
PL (1)	PL333412A1 (cs)
SI (1)	SI9720071A (cs)
SK (1)	SK59599A3 (cs)
WO (1)	WO1998020009A1 (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6870098A (en) *	1997-03-31	1998-10-22	Du Pont Merck Pharmaceutical Company, The	Indazoles of cyclic ureas useful as hiv protease inhibitors
CA2335617C (en) *	1998-06-24	2009-12-15	Novirio Pharmaceuticals Limited	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
FR2810039B1 (fr)	2000-06-13	2007-05-25	Centre Nat Rech Scient	Composes urees cycliques et leur procede de preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69221309T2 (de) *	1991-10-11	1997-12-11	The Du Pont Merck Pharmaceutical Co., Wilmington, Del.	Cyclische harnstoffe und analoga verwendbar als retrovirale proteasehemmer
US5610294A (en) *	1991-10-11	1997-03-11	The Du Pont Merck Pharmaceutical Company	Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors

1997
- 1997-11-04 CA CA002270963A patent/CA2270963A1/en not_active Abandoned
- 1997-11-04 BR BR9712755-8A patent/BR9712755A/pt unknown
- 1997-11-04 KR KR1019990704049A patent/KR20000053123A/ko not_active Withdrawn
- 1997-11-04 CZ CZ991574A patent/CZ157499A3/cs unknown
- 1997-11-04 EP EP97945596A patent/EP0937066A1/en not_active Ceased
- 1997-11-04 IL IL12972697A patent/IL129726A0/xx unknown
- 1997-11-04 HU HU9904143A patent/HUP9904143A3/hu unknown
- 1997-11-04 PL PL97333412A patent/PL333412A1/xx unknown
- 1997-11-04 SI SI9720071A patent/SI9720071A/sl unknown
- 1997-11-04 EE EEP199900187A patent/EE9900187A/xx unknown
- 1997-11-04 JP JP52168298A patent/JP2001503429A/ja active Pending
- 1997-11-04 AU AU51033/98A patent/AU722489B2/en not_active Ceased
- 1997-11-04 CN CN97199418A patent/CN1235601A/zh active Pending
- 1997-11-04 WO PCT/US1997/020036 patent/WO1998020009A1/en not_active Ceased
- 1997-11-04 EA EA199900451A patent/EA001154B1/ru not_active IP Right Cessation
- 1997-11-04 NZ NZ335919A patent/NZ335919A/xx unknown
- 1997-11-04 SK SK595-99A patent/SK59599A3/sk unknown
1999
- 1999-04-29 LV LVP-99-75A patent/LV12374B/en unknown
- 1999-05-07 NO NO992229A patent/NO992229L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
LV12374A (lv)	1999-11-20
NO992229D0 (no)	1999-05-07
SK59599A3 (en)	1999-12-10
BR9712755A (pt)	1999-10-19
IL129726A0 (en)	2000-02-29
NZ335919A (en)	2000-09-29
HUP9904143A2 (hu)	2000-06-28
EA001154B1 (ru)	2000-10-30
CZ157499A3 (cs)	1999-11-17
WO1998020009A1 (en)	1998-05-14
HUP9904143A3 (en)	2002-11-28
EA199900451A1 (ru)	1999-12-29
AU722489B2 (en)	2000-08-03
EE9900187A (et)	1999-12-15
CN1235601A (zh)	1999-11-17
KR20000053123A (ko)	2000-08-25
EP0937066A1 (en)	1999-08-25
LV12374B (en)	2000-04-20
NO992229L (no)	1999-06-07
SI9720071A (sl)	1999-12-31
CA2270963A1 (en)	1998-05-14
AU5103398A (en)	1998-05-29
PL333412A1 (en)	1999-12-06

Publication	Publication Date	Title
JP2002504095A (ja)	2002-02-05	Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン
US6825210B2 (en)	2004-11-30	Tricyclic compounds useful as HIV reverse transcriptase inhibitors
JP2002509922A (ja)	2002-04-02	４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリンチオン誘導体、それらの調製法、およびｈｉｖ逆転写酵素阻害剤としてのそれらの使用
US6391919B1 (en)	2002-05-21	Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
JP2001503429A (ja)	2001-03-13	（４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用
JP2002536298A (ja)	2002-10-29	Ｈｉｖプロテアーゼ阻害剤としてｎ末端置換ベンジル基を含むビス−アミノ酸スルホンアミド
US6218386B1 (en)	2001-04-17	A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US5932570A (en)	1999-08-03	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
EP0937067B1 (en)	2003-07-09	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
US6313110B1 (en)	2001-11-06	Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
US6946469B2 (en)	2005-09-20	Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
US20040063734A1 (en)	2004-04-01	4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors
US6265406B1 (en)	2001-07-24	Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors
US7015214B2 (en)	2006-03-21	Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors
US6562848B1 (en)	2003-05-13	Bis-amino acid sulfonamides as HIV protease inhibitors
MXPA99004294A (en)	2000-01-01	(4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
HRP970595A2 (en)	1998-08-31	1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a hiv proteaze inhibitor
LT4676B (lt)	2000-07-25	1-(3-aminoindazol-5-il)-3-fenilmetil-cikliniai karbamidai, naudojami kaip živ proteazės inhibitoriai
MXPA99004286A (en)	2000-01-01	1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
MXPA01007047A (en)	2002-03-05	Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors